Partnership Could Mean High Alpha for ChemoCentryx
ChemoCentryx (Nasdaq:CCXI) is a biopharmaceutical smallcap whose pipeline & process  are oriented on the development of chemokine pathway drugs.  On January 15, 2014 at the 32nd Annual JP Morgan Healthcare Conference, ChemoCentryx CEO Thomas Schall announced his intention to pursue strategic partnerships with other companies in the resumption and advancement of Vercirnon through clinical phase 3 trials.  The announcement begs for new insight on ChemoCentryx... specifically about how much a partnership could be worth to the company and its shareholders. In order to answer, I will derive an estimate for the cost of the phase 3, and build a range estimate of "hypothetical ...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|